New MRI technique for evaluating brain tumors
Multi-Parametric Quantitative MR Imaging in Evaluation of Brain Tumors
This study is testing a new MRI method to see if it can help doctors better diagnose and monitor brain tumors in patients who are newly diagnosed or have already received treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 84 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Case Comprehensive Cancer Center Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Cleveland, Ohio) |
| Trial ID | NCT02956291 on ClinicalTrials.gov |
What this trial studies
This research evaluates a novel magnetic resonance imaging technique called magnetic resonance fingerprinting (MRF) to improve the diagnosis and assessment of brain tumors. The study involves two groups: one with newly diagnosed brain tumors undergoing standard imaging plus MRF, and another with patients post-therapy who will also receive MRF during follow-up imaging. The goal is to compare MRF data with existing imaging tests, clinical information, and biopsy results to assess its accuracy in differentiating tumor types and treatment effects.
Who should consider this trial
Good fit: Ideal candidates include patients with newly diagnosed intra-axial brain tumors or those with known treated brain tumors showing signs of progression.
Not a fit: Patients with contraindications for MRI, such as certain implanted devices or pregnancy, may not benefit from this study.
Why it matters
Potential benefit: If successful, this technique could lead to more accurate diagnoses and better treatment planning for patients with brain tumors.
How similar studies have performed: While the use of MRI in brain tumor assessment is established, the specific application of magnetic resonance fingerprinting is relatively novel and has not been widely tested in this context.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of intra-axial brain tumor at initial diagnosis or patients with known treated brain tumors on follow-up with concern for imaging progression * Ability to understand and the willingness to sign a written informed consent document, or, in cases where the patient may have cognitive impairment, consent by a legal authorized representative or power of attorney * Patients with brain metastases undergoing partial brain radiation (gamma knife or SRS) with ability to undergo research scan at baseline, 1 month and , 3 months, and 6 months Exclusion Criteria: * Patients with ferromagnetic or otherwise non-MRI compatible aneurysm clips. * The presence of an implanted pacemaker or implanted defibrillator device. * Patients with contraindications for MRI due to embedded foreign metallic objects. Bullets, shrapnel, metalwork fragments, or other metallic material adds unnecessary risk to the patient. * Pregnancy. Regular clinical practice already excludes pregnant patients from gadolinium contrast. * Implanted medical device not described above that is not MRI-compatible. * Known history of severe claustrophobia. * Prisoners and members of other vulnerable populations will be excluded from this study. The subject selection population will not regularly include prisoners and other vulnerable population members as these populations will not provide any additional unique information to or uniquely benefit from the study. Non-English speaking population will be excluded from the study due to lack of sufficient resources to pay for translator and interpreter services. * Minors will be excluded.
Where this trial is running
Cleveland, Ohio
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center — Cleveland, Ohio, United States (Recruiting)
Study contacts
- Principal investigator: Chaitra A Badve, MD — University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
- Study coordinator: Chaitra A Badve, MD
- Email: Chaitra.Badve@uhhospitals.org
- Phone: 216-844-8140
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.